The drug beating Ozempic, Pimp my Portfolio with Luke Laretive & Australia's most popular small caps
From Ozempic’s soaring popularity to the top small-cap stocks held by Australia’s best managers, this episode dives into the trends shaping markets today. Plus, Luke Laretive unpacks Blair's portfolio, exploring the growing interest in private equity and whether retail investors can get a slice of the action. Calling…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
More from Equity Mates Investing Podcast
See all episodes →
47%4 investors, $100,000: Who’s winning 6 months in? | Portfolio Challenge
43%3 impressive Aussie companies, how often should you invest & don’t listen to Michael Burry
39%AI investors are getting nervous. Should they be?
Similar episodes from other shows
More like Equity Mates Investing Podcast →
Introducing: Pimp my Portfolio
Here's How the New Weight Loss Drugs Could Change Everything
Novo Nordisk, Eli Lilly and the GLP-1 economy
The State of Weight-Loss Drugs
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.